Aktivierte partielle Thromboplastinzeit: Standortbestimmung

• LITERATUR

• 1 Miiller-Berghaus G, Dati F, Ammer H, Becker U, Beeser H, Hellstern P, Keller F, Kienast J, Köhler M, Kolde H-J, Kühne D, Lang H, Müller-Beißenhirtz W, Patscheke H, Schramm W, Scifried E, Stötzer KE, Witt I, Witt P. Komitee zur Standardisierung der hämostaseologischen Analytik: Aufgaben und Ziele. Laboratoriumsmedizin 1994; 18: 337-8.
• 2 Normenausschuß Medizin (NAMed) in DIN Deutsches Institut für Normung e. V. Bestimmung der aktivierten partiellen Thromboplastinzeit (APTZ). DIN 58909. Berlin. 1989
• 3 National Committee for Clinical Laboratory Standards: Activated Partial Thromboplastin Time Test (APTT). Proposed Guidelines 1982. NCCLS Document H29-P..
• 4 Proctor RR, Rapaport SI. The partial thromboplastin time with koalin: A simple screening test for first stage clotting factor deficiencies. Am J Clin Pathol 1961; 36: 211-9.
• 5 Thomas L, Trobisch H. Partielle Thromboplastinzeit (aPTT, PTT). In: Labor and Diagnose, 4. Auflage. Thomas L. (ed) Marburg, Germany; Die Medizinische Verlagsgesellschaft: 1992: 694-8.
• 6 Poller L, Thomson JM. The activated partial thromboplastin time (APTT). In: ECAT Assay Procedures. Jespersen J, Bertina RM, Havercate F. (eds) Dordrecht. Boston, London: Kluwer Academic Publishers; 1992: 35-50.
• 7 Basu D, Gallus A, Hirsh J, Cade J. A prospective study of the value of monitoring heparin treatment with the activated partial thromboplastin time. N Engl J Med 1972; 287: 324-7.
• 8 Suchman AL, Griner PF. Diagnostic uses of the partial thromboplastin time and prothrombin time. Ann Intern Med 1986; 104: 810-6.
• 9 Ho CH, Wu SY. The influence of time, temperature and packed cell on activated partial thromboplastin time and prothrombin time. Thromb Res 1991; 62: 625-33.
• 10 McKenna R, Bachmann F, Miro-Quesada M. Thrombo-embolism in patients with abnormally short activated partial thromboplastin time. Thromb Haemost 1977; 38: 893.
• 11 Gill JC, Endre-Brooks J, Bauer PJ, Marks WJ, Montgomery RR. The effect of ABO blood group on the diagnosis of von Willebrand Disease. Blood 1987; 69: 1619-5.
• 12 Marlar RA, Bauer PJ, Endres-Brooks JL, Montgomery RR, Miller CM, Schanen MM. Comparison of the sensitivity of commercial APTT reagents in the detection of mild coagulopathies. Am J Clin Pathol 1982; 82: 436-9.
• 13 Baumann L, Zimmermann TS. Partial thromboplastin time reagents: Another look. Laboratory Medicine 1985; 16: 35.
• 14 Smith LG, Kitchens CS. A comparison between two commercially available activators for determining the partial thromboplastin time. Arch Pathol Lab Med 1985; 109: 243-6.
• 15 Hellstern P, Oberfrank K, Köhler M, Heinkel K, Wenzel E. Die aktivierte partielle Thromboplastinzeit (APTT) als Screeningtest für leichte Gerinnungsfaktorenmängel. Lab Med 1989; 13: 83-6.
• 16 Lindhoff-Last E, Krzywanek HJ, Mosch G, Breddin HK. A comparison of different APTT reagents, heparin sensitivity and detection of mild coagulopathies. Lab Med 1992; 16: 423-6.
• 17 Barna L, Triplett DA. Use of activated partial thromboplastin time for the diagnosis of congenital coagulation disorders: problems and possible solutions. Res Clin Lab 1989; 19: 345-54.
• 18 Mannucci PM. Italian (CISMEL) Study Group Activated partial thromboplastin time. A multicenter evaluation of 11 reagents in the screening of mild haemophilia A. Scand J Haematol 1980; 25: 308-17.
• 19 O’Brian PF, North WRS, Ingram GIC. The diagnosis of mild haemophilia by the partial thromboplastin time test. WFH/ICTH study of the Manchester method. Thromb Haemost 1981; 45: 162-8.
• 20 Bain B, Forster T, Sleigh B. Heparin and the Activated Partial Thromboplastin Time-A difference between the in-vitro and in-vivo effects and implications for the therapeutic range. Am J Clin Path 1980; 11: 668.
• 21 Gawoski JM, Arkin CF, Bovill T, Brandt J, Rock WA, Triplett DA. The effects of heparin on the activated partial thromboplastin time of the college of American Pathologists Survey specimens. Arch Pathol Lab Med 1987; 111: 785-90.
• 22 Van den Besselaar AMHP, Meeuwisse-Braun J, Bertina RM. Monitoring heparin therapy: relationships between the activated partial thromboplastin time and heparin assays based on ex-vivo heparin samples. Thromb Haemost 1990; 63: 16-23.
• 23 Scialla SJ. Heparin monitoring by activated partial thromboplastin time. Comparison of ex vivo measurement and in vitro standardization. Am J Clin Pathol 1985; 84: 351-4.
• 24 Bjornsson TR, Nash PV. Variability in heparin sensitivity of APTT reagents. Am J Clin Pathol 1986; 86: 199-204.
• 25 Shojania AM, Tetreault J, Turnbull G. The variations between heparin sensitivity of different lots of activated partial thromboplastin time reagent produced by the same manufacturer. Am J Clin Pathol 1989; 89: 19-23.
• 26 Poller L, Thomson JM, Taberner DA. Use of the activated partial thromboplastin time for monitoring heparin therapy: problems and possible solutions. Res Clin Lab 1989; 19: 363-70.
• 27 Colvin BT. The British Society for Haematology Guidelines on the Monitoring of Heparin 1992: Second Revision. J Clin Pathol 1993; 46: 97-103.
• 28 Mannucci PM, Canciani MT, Mari D, Meuycci P. The varied sensitivity of partial thromboplastin and prothrombin reagents in the demonstration of lupus-like anticoagulants. Scand J Haematol 1979; 22: 423-32.
• 29 Barna LK, Triplett DA. A report on the First international workshop for lupus anticoagulant identification. Clin Exp Rheuma 1991; 09: 557-67.
• 30 Alving BM, Barr CF, Tang DB. Correlation between lupus anticoagulants and anticar-diolipin antibodies in patients with prolonged activated partial thromboplastin times. Am J Med 1990; 88: 112-6.
• 31 Adcock DM, Marlar RA. Activated partial thromboplastin time reagent sensitivity to the presence of the lupus anticoagulant. Arch Pathol Lab Med 1992; 116: 837-40.
• 32 McPhedron P, Clyne LP, Ortoli NA, Cagnon PG, Sanders FJ. Prolongation of the activated partial thromboplastin time associated with poor venipuncture technic. Am J Clin Pathol 1974; 62: 16-20.
• 33 Czapek EE. Iatrogenic prolonged APTT: A non-disease state. JAMA 1974; 227: 1304.
• 34 Koepke JA, Rodgers JL, Ollivier MJ. Pre-instrumental variables in coagulation testing. Am J Clin Pathol 1975; 64: 591-6.
• 35 Noren I, Blombäck M, Fridell E, Wallinder U. Vacutainer sampling for blood coagulation assays. Scand J Clin Lab Invest 1978; 38: 63-8.
• 36 Smith LG, Kitchen CS. Pseudo-prolongation of the partial thromboplastin time. Am J Clin Pathol. 1983
• 37 Witt I, Beeser H, Müller-Berghaus G. Minimalanforderungen zur Gewinnung von Zitratplasma für hämostaseologische Analysen. Lab Med 1995; 19: 245-7.
• 38 Naghibi F, Han Y, Dodds WJ, Lawrence CE. Effects of reagent and instrument on prothrombin times, activated partial thromboplastin times and patient/control ratios. Thromb Haemost 1988; 59: 455-63.
• 39 D’Angelo A, Seveso MP, Viagno S, D’Angelo A, Gilardoni F, Dettori AG, Bonini P. Effect of clot-detection methods and reagents on activated partial thromboplastin time (APTT). Implications in heparin monitoring by APTT. Am J Clin Pathol 1990; 94: 297-306.
• 40 Stevenson KJ, Easton AC, Curry A, Thomson JM, Poller L. The reliability of activated partial thromboplastin time methods and the relationship to lipid composition and ultrastructure. Thromb Haemost 1986; 55: 250-8.
• 41 Pizzuli L, Nitsch J, Liideritz B. Hemmung der Heparinwirkung durch Glyceroltrinitrat. Dtsch Med Wschr 1988; 113: 1837-40.
• 42 Becker RC, Corrao JM, Baker SP, Bovill EG, Gore JM, Lucas FV. Nitroglycerin-induced heparin resistance: a qualitative defect in Antithrombin III. Circulation 1989; 80 (Suppl II) 52.
• 43 Brack MJ, More RS, Hubner JB, Gershlick AH. The effect of low dose nitroglycerine on plasma heparin concentrations and activated partial thromboplastin times. Blood Coagul Fibrinol 1993; 04: 183-6.
• 44 Francis JL, Howard C. The effect of aprotinin on the response of the activated partial thromboplastin time (APTT) to heparin. Blood Coagul Fibrinol 1993; 04: 33-40.
• 45 Keopke JA. Partial thromboplastin time test-Proposed performance guidelines. ICSH Panel on the PTT. Thromb Haemost 1986; 55: 143-4.
• 46 Koepke JA. Performance guidelines for the partial thromboplastin time test. Res Clin Lab 1989; 19: 359-62.
• 47 Patterson BB, Puls JL. Standardization of prothrombin and activated partial thromboplastin time reagents and controls. Am J Clin Pathol 1976; 65: 213-9.
• 48 Poller L. Standardization of the APTT test. Current status. Scand J Haematol 1980; 37/25 (Suppl) 49-63.
• 49 Van den Besselaar AMHP. Standardization of the activated partial thromboplastin time for monitoring of heparin therapy: where should we go?. Res Clin Lab 1989; 19: 371-7.
• 50 Ray M, Carroll P, Smith I, Hawson G. An attempt to standardize APTT reagents used to monitor heparin therapy. Blood Coagul Fibrinol 1992; 03: 743-8.
• 51 Dahlbäck B, Carlsson M, Svensson PJ. Familial thrombophilia due to a previously unrecognized mechanism characterized by poor anticoagulant response to activated protein C: Prediction of a cofactor to activated protein C. Proc Natl Acad Sci USA 1993; 90: 1004.
• 52 Griffin JH, Evatt B, Wideman C, Fernandez JA. Anticoagulant protein C defective in majority of thrombophilic patients. Blood 1993; 82: 1989-93.
• 53 Svennson PJ, Dahlbäck B. Resistance to activated protein C as a basis for venous thrombosis. N Engl J Med 1994; 330: 517-22.
• 54 Dahlbäck B, Hildebrand B. Inherited resistance to activated protein C is corrected by anticoagulant cofactor activity found to be a property of factor V. Proc Natl Acad Sci USA 1994; 91: 1396-400.
• 55 Bertina RM, Koeleman BPC, Koster T, Rosendaal FR, Dirven RJ, de Ronde H, van der Felden PA, Reitsma PH. Mutation in blood coagulation factor V associated with resistance to activated protein C. Nature 1994; 369: 64-7.